- Patients with lung cancer who received adjuvant chemotherapy plus immunotherapy (chemoimmunotherapy) after surgical resection had significantly better OS and recurrence-free survival (RFS) than patients who had adjuvant chemotherapy alone after surgery.
Why this matters
- Patients aged ≤55 years, men, and those with adenocarcinoma or stage III tumors are good candidates for immunotherapy.
- Randomized, phase 3 study.
- 101 patients with resected lung cancer received chemoimmunotherapy (group A; n=50) or adjuvant chemotherapy (group B; n=51).
- Median follow-up, 59.6 months.
- Immunotherapy consisted of the adoptive transfer of autologous activated cytotoxic killer T cells and dendritic cells.
- Funding: None.
- OS significantly higher (HR, 0.439; 95% CI, 0.239-0.807) in group A vs group B (2-, 5-, and 7-year OS 96.0%, 69.4%, and 55.1% in group A vs 64.7%, 45.1%, and 38.1% in group B, respectively).
- RFS also significantly higher (HR, 0.473; 95% CI, 0.275-0.812) in group A vs group B (2-, 5-, and 7-year RFS 70.0%, 57.9%, and 47.5% in group A vs 43.1%, 31.4%, and 28.5% in group B, respectively).
- Subgroup analyses found that patients aged ≤55 years, men, and those with adenocarcinoma or stage III tumors had better OS and RFS with immunotherapy.
- Single-center study with small cohort.